Related Experiment Videos
Effects of case management and new drugs on Medicaid AIDS spending
1Georgetown University Public Policy Institute in Washington, D.C., USA.
Abstract:
This study evaluates the effects of Florida's participation in the Medicaid acquired immunodeficiency syndrome (AIDS) home and community-based waiver and the use of recently developed AIDS drugs on spending per Medicaid beneficiary. We find that monthly Medicaid spending for waiver non-participants was significantly higher than was spending for waiver nonparticipants. The major reason for the cost difference is that nonwaiver enrollees incurred significantly higher inpatient costs than did those enrolled in the waiver. Although waiver enrollees had higher drug spending, these represent only a fraction of the higher inpatient costs incurred by nonwaiver enrollees. Thus, it appears that adherence to appropriate medications reduces the need for inpatient care. The case management approach of the AIDS waiver may have similar effects for persons with other chronic diseases.
Insights
Florida's Medicaid AIDS waiver program significantly reduced costs by lowering inpatient care needs. This suggests that case management and medication adherence benefit patients with chronic diseases.
Area of Science:
- Health Economics
- Public Health Policy
- Infectious Disease Management
Background:
- Medicaid spending for Acquired Immunodeficiency Syndrome (AIDS) patients is a significant concern.
- The development of new AIDS drugs and home/community-based waiver programs presents opportunities for cost management.
- Understanding the financial impact of these interventions is crucial for healthcare policy.
Purpose of the Study:
- To evaluate the impact of Florida's Medicaid AIDS waiver program on healthcare spending.
- To assess the role of new AIDS medications in managing costs for beneficiaries.
- To compare Medicaid spending between waiver participants and non-participants.
Main Methods:
- Comparative analysis of Medicaid spending data.
- Evaluation of cost differences between waiver participants and non-participants.
- Analysis of inpatient versus drug expenditures for AIDS patients.
Main Results:
- Medicaid beneficiaries in the AIDS waiver program had significantly lower monthly spending than non-participants.
- Non-waiver enrollees incurred substantially higher inpatient costs compared to waiver enrollees.
- While waiver enrollees had increased drug spending, it was less than the savings from reduced inpatient care.
Conclusions:
- The Medicaid AIDS waiver program effectively reduces overall healthcare costs for beneficiaries.
- Adherence to appropriate medications, facilitated by waiver programs, appears to decrease the need for costly inpatient services.
- The case management model of the AIDS waiver may offer a cost-effective approach for managing other chronic diseases.